N1 Diffuse Large B Cell Lymphoma C4725004
An aggressive type of non-Hodgkin lymphoma affecting the lymphatic system. Treatment typically involves chemotherapy and may include targeted therapies or radiation.
Key facts at a glance
- ICD-10
- C83.37
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Painless lymphadenopathy
(lymphatic)B symptoms (fever, night sweats, weight loss)
(systemic)Generalized fatigue
(general)Pruritic rash
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy with clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
R-CHOP chemotherapy regimen
Combination immunochemotherapy using rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone represents the standard first-line treatment for diffuse large B-cell lymphoma. This multi-agent approach targets cancer cells through different mechanisms for maximum efficacy.
Additional treatment options
Radiation therapy
Involved-site radiotherapy may be incorporated for localized disease or bulky tumor masses to enhance local control. Treatment planning uses advanced imaging for precise targeting.
procedureSupportive care during treatment
Comprehensive supportive care including antiemetics, growth factors, and infection prophylaxis improves treatment tolerability. Nutritional support and psychological services complement medical therapy.
complementaryResponse assessment and surveillance
Regular PET-CT imaging and clinical assessments evaluate treatment response and detect potential relapse early. Surveillance protocols continue for several years post-treatment.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is N1 Diffuse Large B Cell Lymphoma C4725004?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat N1 Diffuse Large B Cell Lymphoma C4725004. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy